EBPMN ebpmn Data Hub
Global South · BRICS+
EBPMN Data Hub · data.emergingpharma.org

How LMIC stakeholders perceive their national biopharmaceutical innovation and production systems

A research and data platform on National Innovation and Production Systems for biopharmaceuticals in low- and middle-income countries, combining stakeholder perceptions gathered through qualitative interviews with quantitative market data.

Institute of Biomedical Sciences — University of São Paulo USP · ICBFCF

Developed within the Professional Master's Programme in Innovation in Diagnostics and Drug Development — Institute of Biomedical Sciences (ICB) and School of Pharmaceutical Sciences (FCF), University of São Paulo.

11BRICS+ countries in the qualitative study
4stakeholder categories interviewed
5thematic blocks in the interview guide
30–55interviews planned in the initial phase

Institutional partners

Organisations working with the EBPMN Data Hub.

Qualitative Area

National Biopharmaceutical Innovation and Production Systems in the Global South

A comparative analysis of stakeholder perceptions on NIPS — a qualitative approach focused on BRICS+ countries.

ICB & FCF — University of São Paulo Methodological partner: CEE/Fiocruz 45–60 min interview Anonymised (e.g. IN-IND-02) Online or in person
Institute of Biomedical Sciences — University of São Paulo USP · ICBFCF

Developed within the Professional Master's Programme in Innovation in Diagnostics and Drug Development — Institute of Biomedical Sciences (ICB) and School of Pharmaceutical Sciences (FCF), University of São Paulo.

1 · Participant profile

Key informants from government and regulatory agencies, industry, academia and international organisations. Your identity is never published: results use only a country–category code.

Stakeholder category
Interview format
Your answers are kept in this browser until you submit.

2 · Informed consent

Read the full form. You can switch language and interview format, download a blank copy, and after accepting, download your signed copy.

Scroll to the end of the form to enable acceptance.

3 · Pre-questionnaire — Blocks A & B

Initial reflections help the researcher prepare. Short notes are enough — every question will be explored in the interview, and all fields are optional. Blocks C, D and E are covered during the interview itself.

4 · Schedule your interview

Choose up to three preferred time slots, in order of preference. The researcher will confirm one of them by e-mail and send the meeting link or venue details.

Times shown in your time zone:

5 · Review and submit

Check your details. After submitting, you will receive a reference number and can download a full PDF record.

Quantitative Area

Quantitative data area — in development

This area will bring market, production and pipeline data on biopharmaceuticals in the Global South through institutional data partnerships. It is being developed and will open to EBPMN members and partners in stages.

Stage: partnership structuring and data architecture

Data partnerships

In development

IQVIA LATAM

Market intelligence on biologics and biosimilars in Latin America.

Open to partners

Institutional partners

Regulatory agencies, development banks, industry associations and research institutes interested in contributing data.

Planned modules

Market size and growthBiologics and biosimilars by country and therapeutic class
Pipeline and approvalsRegulatory approvals and development pipeline
Production capacityLocal and regional manufacturing capabilities
Trade and value chainsSouth-South trade flows in biopharmaceuticals

Be notified when the area opens

EBPMN

Events

Sector events where in-person interview waves may take place, and EBPMN webinars.

EBPMN Data Hub

Contacts

Principal researcher

Claudio Luiz Guilherme Brandão

ICB/USP · EBPMN
cbrandao@icb.usp.br
+55 11 95896-6307

Supervisor

Prof. Dr. Adalberto Pessoa Júnior

University of São Paulo

Research ethics

Research Ethics Committee — ICB/USP

Partner & member access

Restricted access for EBPMN members, data partners and the research team is in development.